IL273948B2 - Compositions and methods for selective degradation of proteins - Google Patents

Compositions and methods for selective degradation of proteins

Info

Publication number
IL273948B2
IL273948B2 IL273948A IL27394820A IL273948B2 IL 273948 B2 IL273948 B2 IL 273948B2 IL 273948 A IL273948 A IL 273948A IL 27394820 A IL27394820 A IL 27394820A IL 273948 B2 IL273948 B2 IL 273948B2
Authority
IL
Israel
Prior art keywords
cell
fusion polypeptide
pharmaceutically acceptable
acceptable salt
lenalidomide
Prior art date
Application number
IL273948A
Other languages
Hebrew (he)
Other versions
IL273948B1 (en
IL273948A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL273948A publication Critical patent/IL273948A/en
Publication of IL273948B1 publication Critical patent/IL273948B1/en
Publication of IL273948B2 publication Critical patent/IL273948B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Emergency Medicine (AREA)

Claims (49)

1. 273948/ CLAIMS 1. A fusion polypeptide comprising: (i) a CRBN (cereblon)-binding polypeptide, and (ii) a chimeric antigen receptor (CAR) that comprises, in a N-terminal to C-terminal direction, an antigen binding domain, a transmembrane domain, and one or more intracellular signaling domains, wherein the CRBN-binding polypeptide comprises 45 to 65 amino acid residues of IKZF3 (SEQ ID NO: 19) and includes the amino acid sequence of SEQ ID NO: 5.
2. The fusion polypeptide of claim 1, wherein the CRBN-binding polypeptide comprises to 65 amino acid residues of IKZF3 (SEQ ID NO: 19).
3. The fusion polypeptide of claim 1, wherein the CRBN-binding polypeptide comprises to 65 amino acid residues of IKZF3 (SEQ ID NO: 19).
4. The fusion polypeptide of any one of claims 1-3, wherein the CRBN-binding polypeptide further comprises the amino acid sequence of SEQ ID NO: 11.
5. The fusion polypeptide of any one of claims 1-4, wherein the CRBN-binding polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1 or 3.
6. The fusion polypeptide of any one of claims 1-5, wherein: (i) the CRBN-binding polypeptide is fused to the CAR; (ii) the CRBN-binding polypeptide and the CAR are linked by a peptide bond; (iii) the CAR is linked directly or indirectly to the CRBN-binding polypeptide; (iv) the CRBN-binding polypeptide and the CAR are operatively linked via a linker, e.g., a linker comprising the amino acid sequence of SEQ ID NO: 28; and/or 273948/ (v) the CRBN-binding polypeptide is linked to the C-terminus or N-terminus of the CAR.
7. The fusion polypeptide of any one of claims 1-6, wherein the degradation of the fusion polypeptide in the absence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, is no more than 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, or 70% of the degradation of the fusion polypeptide in the presence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein: (a) the degradation is measured by an assay described herein, e.g., a Western blot analysis or a flow cytometry analysis; (b) the degradation of the fusion polypeptide is mediated by ubiquitination in the presence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof; and/or (c) the degradation is as measured in a mammalian cell, e.g., a human cell.
8. The fusion polypeptide of any one of claims 1-7, wherein the fusion polypeptide further comprises a degradation domain that is separated from the CRBN-binding polypeptide and the CAR by a heterologous protease cleavage site.
9. The fusion polypeptide of claim 8, wherein the fusion polypeptide comprises, from N-terminus to C-terminus: (a) the degradation domain, the heterologous protease cleavage site, the CAR, and the CRBN-binding polypeptide; (b) the degradation domain, the heterologous protease cleavage site, the CRBN-binding polypeptide, and the CAR; (c) the CRBN-binding polypeptide, the CAR, the heterologous protease cleavage site, and the degradation domain; or 273948/ (d) the CAR, the CRBN-binding polypeptide, the heterologous protease cleavage site, and the degradation domain.
10. The fusion polypeptide of claim 8 or 9, wherein the degradation domain has a first state associated with a first level of expression of the fusion polypeptide and a second state associated with a second level of expression of the fusion polypeptide, wherein the second level is increased, e.g., by at least 2-, 3-, 4-, 5-, 10-, 20- or 30-fold over the first level in the presence of the stabilization compound, optionally wherein in the absence of the stabilization compound, the fusion polypeptide is degraded by a cellular degradation pathway, e.g., at least 50%, 60%, 70%, 80%, 90% or greater of the fusion polypeptide is degraded, e.g., as measured by a Western blot analysis or a flow cytometry analysis.
11. The fusion polypeptide of claim 10, wherein: (a) the level of expression and/or degradation is as measured in a mammalian cell, e.g., a human cell; and/or (b) in the presence of the stabilization compound: (I) the degradation domain assumes a conformation more resistant to cellular degradation relative to a conformation in the absence of the stabilization compound; or (II) the degradation domain assumes a conformation that exposes the heterologous cleavage site, thereby rendering the fusion polypeptide more permissive to cleavage at the heterologous protease cleavage site relative to a conformation in the absence of the stabilization compound, leading to removal of the degradation domain from the rest of the fusion polypeptide.
12. The fusion polypeptide of any one of claims 8-11, wherein the degradation domain is chosen from an estrogen receptor (ER) domain, an FKB protein (FKBP) domain, or a dihydrofolate reductase (DHFR) domain. 273948/
13. The fusion polypeptide of any one of claims 8-12, wherein: (a) the degradation domain is an ER domain and comprises an amino acid sequence that is at least 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 46 or 48; (b) the degradation domain is an FKBP domain and comprises an amino acid sequence that is at least 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 50; or (c) the degradation domain is a DHFR domain and comprises an amino acid sequence that is at least 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 51.
14. The fusion polypeptide of claim 12 or 13, wherein said stabilization compound is: (a) bazedoxifene or 4-hydroxy tamoxifen (4-OHT), or a pharmaceutically acceptable salt thereof, when the degradation domain is said ER domain; (b) Shield-1, or a pharmaceutically acceptable salt thereof, when the degradation domain is said FKBP domain; or (c) trimethoprim, or a pharmaceutically acceptable salt thereof, when the degradation domain is said DHFR domain.
15. The fusion polypeptide of any one of claims 8-14, wherein the heterologous protease cleavage site is cleaved by a mammalian intracellular protease, optionally wherein the heterologous protease cleavage site: (a) is cleaved by a protease selected from the group consisting of furin, PCSK1, PCSK5, PCSK6, PCSK7, cathepsin B, Granzyme B, Factor XA, Enterokinase, genenase, sortase, precission protease, thrombin, TEV protease, and elastase 1; and/or (b) comprises a sequence comprising a cleavage motif selected from the group consisting of Arg-X-Lys/Arg-Arg consensus motif (X can be any amino acid; SEQ ID NO: 52), Arg-X-X-X-Lys/Arg-Arg consensus motif (X can be any amino 273948/ acid; SEQ ID NO: 53), Arg-Arg-X consensus motif (SEQ ID NO: 54), Ile-Glu-Pro-Asp-X consensus motif (SEQ ID NO: 55), Ile-Glu/Asp-Gly-Arg (SEQ ID NO: 56), Asp-Asp-Asp-Asp-Lys (SEQ ID NO: 57), Pro-Gly-Ala-Ala-His-Tyr (SEQ ID NO: 58), Leu-Pro-X-Thr-Gly/Ala consensus motif (SEQ ID NO: 59), Leu-Glu-Val-Phe-Gln-Gly-Pro (SEQ ID NO: 60), Leu-Val-Pro-Arg-Gly-Ser (SEQ ID NO: 61), E-N-L-Y-F-Q-G (SEQ ID NO: 62), and [Ala/Gly/Ser/Val]-X (X can be any amino acid; SEQ ID NO: 63).
16. The fusion polypeptide of claim 15, wherein the heterologous protease cleavage site is cleaved by furin, optionally wherein the heterologous protease cleavage site comprises a furin cleavage site selected from the group consisting of RTKR (SEQ ID NO: 123); GTGAEDPRPSRKRRSLGDVG (SEQ ID NO: 125); GTGAEDPRPSRKRR (SEQ ID NO: 127); LQWLEQQVAKRRTKR (SEQ ID NO: 129); GTGAEDPRPSRKRRSLGG (SEQ ID NO: 131); GTGAEDPRPSRKRRSLG (SEQ ID NO: 133); SLNLTESHNSRKKR (SEQ ID NO: 135); CKINGYPKRGRKRR (SEQ ID NO: 137); and SARNRQKR (SEQ ID NO: 34).
17. The fusion polypeptide of any one of claims 8-14, wherein the heterologous protease cleavage site is cleaved by a mammalian extracellular protease, optionally wherein: (a) the mammalian extracellular protease is selected from the group consisting of Factor XA, Enterokinase, genenase, sortase, precission protease, thrombin, TEV protease, and elastase 1; and/or (b) the heterologous protease cleavage site comprises an amino acid sequence selected from the group consisting of Ile-Glu/Asp-Gly-Arg (SEQ ID NO: 56), Asp-Asp-Asp-Asp-Lys (SEQ ID NO: 57), Pro-Gly-Ala-Ala-His-Tyr (SEQ ID NO: 58), Leu-Pro-X-Thr-Gly/Ala consensus motif (SEQ ID NO: 59), Leu-Glu-Val-Phe-Gln-Gly-Pro (SEQ ID NO: 60), Leu-Val-Pro-Arg-Gly-Ser (SEQ ID NO: 273948/ 61), Glu-Asn-Leu-Tyr-Phe-Gln-Gly (SEQ ID NO: 62), and [Ala/Gly/Ser/Val]-X (X can be any amino acid; SEQ ID NO: 63).
18. The fusion polypeptide of any one of claims 1-17, wherein: (a) said intracellular signaling domain comprises one or more primary signaling domains, e.g. wherein one of said one or more primary signaling domains comprises a CD3-zeta stimulatory domain; and/or (b) said intracellular signaling domain comprises one or more of costimulatory signaling domains, e.g. wherein one or more of said costimulatory signaling domains is an intracellular domain from a costimulatory protein selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, GITR, CD30, CD40, ICOS, BAFFR, HVEM, ICAM-1, lymphocyte function-associated antigen-(LFA-1), CD2, CDS, CD7, CD287, LIGHT, NKG2C, NKG2D, SLAMF7, NKp80, NKp30, NKp44, NKp46, CD160, B7-H3, and a ligand that specifically binds with CD83.
19. The fusion polypeptide of any one of claims 1-18, wherein said antigen binding domain is an scFv.
20. The fusion polypeptide of any one of claims 1-19, wherein said antigen binding domain binds an antigen selected from the group consisting of CD19; CD123; CD22; CD30; CD171; CS-1; C-type lectin-like molecule-1, CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3; TNF receptor family member; B-cell maturation antigen; Tn antigen ((Tn Ag) or (GalNAcα-Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-Like Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein (TAG72); CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit 273948/ alpha-2; Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 21; vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20; Folate receptor alpha; Receptor tyrosine-protein kinase ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene polypeptide consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3; transglutaminase 5 (TGS5); high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GDganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 273948/ 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-(MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate carcinoma tumor antigen-1, melanoma antigen recognized by T cells 1; Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)-Like, Squamous Cell Carcinoma Antigen Recognized By T Cells (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation Endproducts (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1).
21. A nucleic acid molecule encoding the fusion polypeptide of any one of claims 1-20. 273948/
22. A vector comprising the nucleic acid molecule of claim 21, optionally wherein said vector is a viral or lentiviral vector.
23. A viral particle comprising the vector of claim 22.
24. A cell comprising the fusion polypeptide of any one of claims 1-20, the nucleic acid molecule of claim 21, or the vector of claim 22.
25. The cell of claim 24, wherein said cell: (i) is a mammalian cell, e.g., a human T cell or human NK cell; (ii) comprises a component of a CRISPR/Cas system; (iii) is a human cancer cell, e.g., a human tumor cell; and/or (iv) comprises a ubiquitin ligase complex, e.g., an E3 ubiquitin ligase complex, wherein the ubiquitin ligase complex comprises CRBN.
26. The cell of claim 24 or 25, wherein the cell comprises the fusion polypeptide of any one of claims 1-7 or 18-20 or the cell comprises a nucleic acid molecule encoding the fusion polypeptide of any one of claims 1-7 or 18-20, wherein when the cell is contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof: (a) the degradation of the fusion polypeptide is increased, e.g. by at least 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, compared to the degradation of the fusion polypeptide when the cell is not contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, e.g., as measured by a Western blot analysis or a flow cytometry analysis; or (f) the expression level of the fusion polypeptide is no more than 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%, of the expression level of the fusion polypeptide when the cell is not contacted with lenalidomide or pomalidomide, or 273948/ a pharmaceutically acceptable salt thereof, e.g., as measured by a Western blot analysis or a flow cytometry analysis.
27. The cell of claim 24 or 25, wherein the cell comprises the fusion polypeptide of any one of claims 8-20 or the cell comprises a nucleic acid molecule encoding the fusion polypeptide of any one of claims 8-20, wherein in the absence of a stabilization compound, the fusion polypeptide is degraded by a cellular degradation pathway, e.g., at least 50%, 60%, 70%, 80%, 90% or greater of the fusion polypeptide is degraded, e.g., as measured by a Western blot analysis or a flow cytometry analysis, optionally wherein: (i) the cell further comprises a protease capable of cleaving said heterologous protease cleavage site; (ii) the cell further comprises the stabilization compound; (iii) the stabilization compound is bazedoxifene, or a pharmaceutically acceptable salt thereof, optionally wherein the degradation domain comprises the amino acid sequence of SEQ ID NO: 46; and/or (iv) the cell further comprises lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof.
28. The cell of claim 27, wherein when the cell is contacted with both the stabilization compound and lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof: (a) the degradation of the fusion polypeptide is increased, e.g. by at least 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, compared to the degradation of the fusion polypeptide when the cell is only contacted with the stabilization compound but not lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, e.g., as measured by a Western blot analysis or a flow cytometry analysis; or (b) the expression level of the fusion polypeptide is no more than 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%, of the expression level of the fusion polypeptide when the cell is only contacted with the stabilization compound but 273948/ not lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, e.g., as measured by a Western blot analysis or a flow cytometry analysis.
29. A pharmaceutical composition comprising the fusion polypeptide of any one of claims 1-or the cell of any one of claims 24-28, and a pharmaceutically acceptable carrier, excipient or stabilizer.
30. A method of degrading a fusion polypeptide, comprising contacting the fusion polypeptide of any one of claims 1-7 or 18-20 or a cell comprising said fusion polypeptide with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein: (i) in the presence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, the expression level of said fusion polypeptide is substantially decreased, e.g., by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 percent, relative to the expression level of said fusion polypeptide in the absence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, e.g., as measured by a Western blot analysis or a flow cytometry analysis; and/or (ii) the fusion polypeptide or the cell is contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof ex vivo or in vivo.
31. A method of regulating the expression of a fusion polypeptide, comprising: (i) contacting the fusion polypeptide of any one of claims 8-20 or a cell comprising said fusion polypeptide with a stabilization compound, optionally wherein: (a) in the presence of the stabilization compound the expression level of the fusion polypeptide is increased, e.g. by at least 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, compared to the expression level of the fusion 273948/ polypeptide in the absence of the stabilization compound, e.g., as measured by a Western blot analysis or a flow cytometry analysis; (b) the stabilization compound is bazedoxifene, or a pharmaceutically acceptable salt thereof, and optionally wherein the degradation domain comprises the amino acid sequence of SEQ ID NO: 46; and/or (c) the fusion polypeptide or the cell is contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof and/or the stabilization compound ex vivo or in vivo.
32. The method of claim 31, further comprising after step (i): (ii) contacting the fusion polypeptide or the cell comprising said fusion polypeptide with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein in the presence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, the expression level of the fusion polypeptide is decreased, e.g., by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 percent, relative to the expression level of the fusion polypeptide after step (i) and before step (ii), e.g., as measured by a Western blot analysis or a flow cytometry analysis.
33. A method of making a cell, wherein: (i) the cell is a cell of any one of claims 24-28, said method comprising providing a cell, e.g., an immune effector cell, with the nucleic acid molecule of claim 21, the vector of claim 22, or the viral particle of claim 23; or (ii) the method comprises providing a cell comprising a nucleic acid molecule encoding the fusion polypeptide of any one of claims 1-20 and contacting the cell ex vivo with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof. 273948/
34. A cell comprising the fusion polypeptide of any one of claims 1-7 or 18-20, for use in a method of treating a disease associated with expression of a tumor antigen in a subject, wherein the method comprises administering an effective amount of said cell to the subject, thereby treating the disease.
35. The cell for use of claim 34, wherein: (i) the cell is contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, ex vivo before administration, optionally wherein: (a) in the presence of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, the expression level of the fusion polypeptide is decreased, e.g., by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 percent, relative to the expression level of the fusion polypeptide before the cell is contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof; and/or (b) after the cell is contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof ex vivo and before the cell is administered to the subject, the amount of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof is reduced.
36. The cell for use of claim 34 or 35, wherein after administration of the cell, the method further comprises administering to the subject an effective amount of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein: (a) the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof decreases, e.g., by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 percent, the expression level of the fusion polypeptide relative to the expression level of the fusion polypeptide after administration of the cell and prior to 273948/ administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof; (b) the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof reduces or prevents an adverse effect; and/or (c) the subject is administered lenalidomide, or a pharmaceutically acceptable salt thereof at 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg per day
37. The cell for use of any one of claims 34-36, wherein the method further comprises, after administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, discontinuing the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein: (a) discontinuing the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof increases, e.g., by at least about 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, the expression level of the fusion polypeptide relative to the expression level of the fusion polypeptide after administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof and prior to discontinuing lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof administration (e.g., wherein discontinuing the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof restores the expression level of the fusion polypeptide to the expression level after administration of the cell and prior to administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof); and/or (b) the discontinuation of the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof treats or prevents a tumor relapse. 273948/
38. The cell for use of claim 37, wherein after discontinuing lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof administration, the method comprises repeating the step of administering lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof and/or the step of discontinuing the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, thereby treating the disease.
39. Lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, for use in a method of treating a side effect of a cell comprising the fusion polypeptide of any one of claims 1-7 or 18-20 in a subject, wherein the subject has a disease associated with expression of a tumor antigen and comprises said cell, and wherein the method comprises (i) administering an effective amount of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof to the subject, optionally wherein: (a) the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof decreases, e.g., by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 percent, the expression level of the fusion polypeptide relative to the expression level of the fusion polypeptide before the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof; (b) the method further comprises, after step (i), the step of (ii) discontinuing the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein: (I) the discontinuation of the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof treats or prevents a tumor relapse; and/or (II) the method further comprises, after step (ii), the step of (iii) repeating step (i) and/or (ii), thereby treating the disease; and/or 273948/ (c) the subject is administered lenalidomide or pharmaceutically acceptable salt thereof at 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg per day.
40. A combination of (1) a stabilization compound as defined in claim 14 and (2) an effective amount of a cell comprising the fusion polypeptide of any one of claims 8-20, for use in a method of treating a disease associated with expression of a tumor antigen in a subject, wherein the method comprises (i) administering said combination to the subject, thereby treating the disease, optionally wherein the expression level of the fusion polypeptide in the presence of the stabilization compound is higher, e.g., by at least about 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, than the expression level of the fusion polypeptide in the absence of the stabilization compound.
41. The combination for use of claim 40, wherein the method further comprises: (a) after step (i), the step of (ii) discontinuing the administration of the stabilization compound, optionally wherein: (I) discontinuing the administration of the stabilization compound reduces, e.g., at least about 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, the expression level of the fusion polypeptide relative to the expression of the fusion polypeptide after step (i) and prior to step (ii); (II) the subject responded to the treatment of step (i), and/or (III) the discontinuation of the administration of the stabilization compound is in response to a response of the subject to the treatment of step (i); (b) after step (i), the step of (iii) discontinuing the administration of the stabilization compound, optionally wherein the discontinuation of the administration of the stabilization compound reduces or prevents an adverse effect; or (c) after step (i), the step of (iv) discontinuing the administration of the stabilization compound and administering to the subject an effective amount of lenalidomide 273948/ or pomalidomide, or a pharmaceutically acceptable salt thereof, optionally wherein: (I) step (iv) reduces or prevents an adverse effect, e.g. an acute toxicity; (II) after step (iv), the method comprises the step of (v) discontinuing the administration of lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof; and/or (III) lenalidomide, or pharmaceutically acceptable salt thereof, is administered at 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg per day.
42. The combination for use of claim 41, wherein: (a) the method further comprises, after step (ii), (iii), (iv), or (v), the step of (vi) administering an effective amount of the stabilization compound, optionally wherein: (I) the administration of the stabilization compound increases, e.g., by at least about 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, the expression level of the fusion polypeptide relative to the expression level of the fusion polypeptide after step (ii), (iii), (iv), or (v) and prior to step (vi); (II) the administration of the stabilization compound treats or prevents a tumor relapse; and/or (III) the method further comprises after step (vi), the step of (vii) repeating step (iii), (iv), (v), or (vi), thereby treating the disease; (b) the method further comprises, prior to step (i), the step of (viii) contacting the cell with a stabilization compound as defined in claim 14 ex vivo, optionally wherein the expression level of the fusion polypeptide in the presence of the stabilization compound is higher, e.g. by at least about 1.5-, 2-, 3-, 4-, 5-, 10-, 20-, 30-, 40-, or 50-fold, than the expression level of the fusion polypeptide in the absence of the stabilization compound; and/or 273948/ (c) the cell is not contacted with the stabilization compound ex vivo before administration of the cell, optionally wherein the cell is not contacted with lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof ex vivo before administration of the cell.
43. The fusion polypeptide of any one of claims 1-20, nucleic acid molecule of claim 21, vector of claim 22, viral particle of claim 23, cell of any one of claims 24-28, or pharmaceutical composition of claim 29 for use as a medicament.
44. The fusion polypeptide of any one of claims 1-20, nucleic acid molecule of claim 21, vector of claim 22, viral particle of claim 23, cell of any one of claims 24-28, or pharmaceutical composition of claim 29 for use in the treatment a disease associated with expression of a tumor antigen.
45. The cell for use of any one of claims 34-38, lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, for use of claim 39, the combination for use of any one of claims 40-42, or the fusion polypeptide, nucleic acid molecule, vector, viral particle, cell, or pharmaceutical composition for use of claim 44, wherein the disease associated with expression of a tumor antigen is a cancer.
46. The cell for use, lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof for use, the combination for use, or the fusion polypeptide, nucleic acid molecule, vector, viral particle, cell, or pharmaceutical composition for use of claim 45, wherein the cancer is a hematological cancer.
47. The cell for use, lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof for use, the combination for use, or the fusion polypeptide, nucleic acid molecule, 273948/ vector, viral particle, cell, or pharmaceutical composition for use of claim 45, wherein the cancer is chosen from a leukemia or lymphoma.
48. The cell for use, lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof for use, the combination for use, or the fusion polypeptide, nucleic acid molecule, vector, viral particle, cell, or pharmaceutical composition for use of claim 45, wherein the cancer is chosen from: chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), multiple myeloma, acute lymphoblastic leukemia (ALL), Hodgkin lymphoma, B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), small lymphocytic lymphoma (SLL), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma (DLBCL), DLBCL associated with chronic inflammation, chronic myeloid leukemia, myeloproliferative neoplasms, follicular lymphoma, pediatric follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma (extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue), Marginal zone lymphoma, myelodysplasia, myelodysplastic syndrome, non-Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, splenic lymphoma/leukemia, splenic diffuse red pulp small B-cell lymphoma, hairy cell leukemia-variant, lymphoplasmacytic lymphoma, a heavy chain disease, plasma cell myeloma, solitary plasmocytoma of bone, extraosseous plasmocytoma, nodal marginal zone lymphoma, pediatric nodal marginal zone lymphoma, primary cutaneous follicle center lymphoma, lymphomatoid granulomatosis, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, primary effusion lymphoma, B-cell lymphoma, acute myeloid leukemia (AML), or unclassifiable lymphoma. 273948/
49. The cell for use of any one of claims 34-38, lenalidomide or pomalidomide, or a pharmaceutically acceptable salt thereof, for use of claim 39, or the combination for use of any one of claims 40-42, wherein said cell is autologous or allogeneic to said subject.
IL273948A 2017-10-18 2018-10-18 Compositions and methods for selective degradation of proteins IL273948B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574188P 2017-10-18 2017-10-18
PCT/US2018/056472 WO2019079569A1 (en) 2017-10-18 2018-10-18 Compositions and methods for selective protein degradation

Publications (3)

Publication Number Publication Date
IL273948A IL273948A (en) 2020-05-31
IL273948B1 IL273948B1 (en) 2025-08-01
IL273948B2 true IL273948B2 (en) 2025-12-01

Family

ID=64477268

Family Applications (2)

Application Number Title Priority Date Filing Date
IL321733A IL321733A (en) 2017-10-18 2018-10-18 Compositions and methods for selective protein degradation
IL273948A IL273948B2 (en) 2017-10-18 2018-10-18 Compositions and methods for selective degradation of proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL321733A IL321733A (en) 2017-10-18 2018-10-18 Compositions and methods for selective protein degradation

Country Status (14)

Country Link
US (2) US11999802B2 (en)
EP (1) EP3697436A1 (en)
JP (2) JP7585034B2 (en)
KR (1) KR20200086278A (en)
CN (1) CN111629749A (en)
AR (1) AR123115A1 (en)
AU (2) AU2018351050B2 (en)
BR (1) BR112020007576A2 (en)
CA (1) CA3079407A1 (en)
IL (2) IL321733A (en)
MX (1) MX2020004013A (en)
SG (1) SG11202003415XA (en)
TW (2) TWI829655B (en)
WO (1) WO2019079569A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2769574T3 (en) 2013-03-15 2020-06-26 Michael C Milone Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP6831777B2 (en) 2014-07-21 2021-02-17 ノバルティス アーゲー Treatment of cancer using the CD33 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
PL3280729T3 (en) 2015-04-08 2022-08-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
JP7467117B2 (en) 2016-10-07 2024-04-15 ノバルティス アーゲー Chimeric antigen receptors for the treatment of cancer - Patents.com
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019089592A1 (en) 2017-10-31 2019-05-09 The General Hospital Corporation Molecular switch-mediated control of engineered cells
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag Bcma chimeric antigen receptors and uses thereof
BR122022012697B1 (en) * 2018-07-10 2023-04-04 Novartis Ag USES OF 3-(5-HYDROXY-1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6- DIONE DERIVATIVES, AND KIT
AR116109A1 (en) * 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
SI3844267T1 (en) 2018-08-31 2025-10-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3924054B1 (en) * 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University GLUTARIMIDE SKELETON SULFUR-CONTAINING COMPOUND AND USE THEREOF
CA3136626A1 (en) * 2019-04-12 2020-10-15 Emory University Compositions and methods for promoting hematopoietic cell cytotoxicity
WO2021023233A1 (en) 2019-08-05 2021-02-11 上海科技大学 Egfr protein degradant and anti-tumor application thereof
IL292387B2 (en) * 2019-10-23 2025-08-01 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Chimeric polypeptide for regulating immune cells
WO2021087093A1 (en) * 2019-10-30 2021-05-06 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use
JP7629459B2 (en) * 2019-11-19 2025-02-13 ブリストル-マイヤーズ スクイブ カンパニー Compounds useful as inhibitors of Helios protein
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
JP7805928B2 (en) 2019-11-26 2026-01-26 ノバルティス アーゲー CD19 and CD22 chimeric antigen receptors and uses thereof
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11672828B2 (en) 2020-02-10 2023-06-13 Trustees Of Boston University Cellular receptors and uses thereof
IL295878A (en) * 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW202140441A (en) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 Substituted oxoisoindoline compounds
EP4144728A4 (en) * 2020-04-30 2023-08-23 Shanghaitech University GLUTARIMIDE FRAMEWORK BASED HETEROCYCLIC COMPOUND AND APPLICATIONS THEREOF
EP4168451A2 (en) 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
EP4168411A4 (en) 2020-06-22 2024-07-24 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION
CN113896711A (en) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 Heterocyclic immunomodulators
EP4188549A1 (en) * 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113307793B (en) * 2020-08-27 2022-04-12 杭州医学院 Compound for inducing Tau protein degradation based on CRBN ligand, preparation method, pharmaceutical composition and application thereof
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Small compounds based on piperidine that decompose helium and methods of use
CN116669769A (en) * 2020-10-16 2023-08-29 达纳-法伯癌症研究所公司 Piperidinyl small molecule degradation agent and method of use of HELIOS
WO2022098843A1 (en) * 2020-11-05 2022-05-12 Kronos Bio, Inc. Compounds and methods for modulating cdk9 activity
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
JP2024513232A (en) * 2021-04-06 2024-03-22 センティ バイオサイエンシズ インコーポレイテッド Drug-regulatable transcriptional repressors
PE20231941A1 (en) 2021-04-06 2023-12-05 Bristol Myers Squibb Co PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS
WO2022254362A1 (en) 2021-06-03 2022-12-08 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
CN117957225A (en) * 2021-07-07 2024-04-30 渤健马萨诸塞州股份有限公司 Compounds for targeting IRAK4 protein degradation
US12174208B2 (en) 2021-07-13 2024-12-24 Identigen Limited Automated system for collecting tissue samples, and corresponding method and computer-readable medium
CN117396208A (en) * 2021-07-16 2024-01-12 达纳-法伯癌症研究所公司 Small molecule degraders of cyclin-dependent kinase 4/6 (CDK4/6) and IKZF2 (HELIOS) and methods of using them
JP2024528988A (en) * 2021-08-06 2024-08-01 セルジーン コーポレーション Compositions and methods for the selective degradation of modified proteins
US11564983B1 (en) * 2021-08-20 2023-01-31 Betagen Scientific Limited Efficient expression system of SARS-CoV-2 receptor binding domain (RBD), methods for purification and use thereof
WO2023096822A1 (en) * 2021-11-23 2023-06-01 St. Jude Children's Research Hospital, Inc. Substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetamide analogs as modulators of gspt1 and/or ikzf1 protein
EP4455133A4 (en) * 2021-12-24 2026-04-15 Suzhou Kintor Pharmaceuticals Inc Multiprotein degradation agent with imidskeleton
CN116640122A (en) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 IKZF 2 Degradation agent, pharmaceutical composition containing degradation agent and application of degradation agent
KR20240001072A (en) * 2022-06-24 2024-01-03 주식회사 아이비스바이오 Novel pomalidomide derivative and manufacturing method thereof
US20260028326A1 (en) * 2022-08-10 2026-01-29 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compound based on isoindoline-substituted glutarimide backbone and use thereof
WO2024081690A2 (en) * 2022-10-11 2024-04-18 The General Hospital Corporation Engineered bifunctional receptors and uses thereof
CN117069840B (en) * 2023-10-13 2024-01-30 北京百普赛斯生物科技股份有限公司 Antibody for specifically detecting IL-21 and application thereof
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN118831181B (en) * 2024-09-20 2025-02-11 江苏集萃药康生物科技股份有限公司 A method for constructing a triple-mutant Alzheimer's disease mouse model and its application
CN119751591B (en) * 2025-03-06 2025-05-16 中南大学 Polypeptide of targeted stability-enhancing BRD7 tumor-inhibiting protein and application of polypeptide in preparation of solid tumor treatment drugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140090111A1 (en) * 2012-09-05 2014-03-27 Carnegie Institution Of Washington Plant Hormone Biosensors
WO2015127351A1 (en) * 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017044801A2 (en) * 2015-09-11 2017-03-16 The Broad Institute, Inc. Methods of identifying drug-modulated polypeptide targets for degradation

Family Cites Families (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
ATE145428T1 (en) 1990-12-14 1996-12-15 Cell Genesys Inc CHIMERIC CHAINS FOR TRANSDUCTION OF RECEPTOR-CONNECTED SIGNALING PATHWAYS
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
ES2185705T3 (en) 1994-05-02 2003-05-01 Bernd Groner BIFUNCTIONAL PROTEIN, PREPARATION AND USE.
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
AU708339B2 (en) 1995-02-24 1999-08-05 General Hospital Corporation, The Redirection of cellular immunity by receptor chimeras
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
EP0937095A4 (en) 1996-10-25 1999-12-22 Cell Genesys Inc Targeted cytolysis of cancer cells
US6365712B1 (en) 1996-10-25 2002-04-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド Artificial antibody polypeptide
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
EP1144655A2 (en) 1998-10-19 2001-10-17 Ariad Gene Therapeutics, Inc. Regulated expression using conditional er retention domains
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
JP2002541845A (en) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド Synthetic transmembrane component
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ATE510855T1 (en) 2000-03-06 2011-06-15 Univ Kentucky Res Found USE OF AN ANTIBODIES OR AN IMMUNOTOXIN THAT RESPECTIVELY THAT SELECTIVELY BINDS TO CD123 TO IMPAIR HEMATOLOGICAL CANCER PROGENIC CELLS
IL136511A0 (en) 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
JP4361273B2 (en) 2001-02-27 2009-11-11 アメリカ合衆国 Thalidomide analogs as potential angiogenesis inhibitors
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
CA2808646C (en) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc Novel tetravalent bispecific antibody
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
EP3530321A1 (en) 2004-12-10 2019-08-28 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
KR20140053410A (en) 2005-08-19 2014-05-07 아보트 러보러터리즈 Dual variable domain immunoglobulin and uses thereof
ATE509033T1 (en) 2006-03-20 2011-05-15 Univ California ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
JP2010505775A (en) 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Production of cancer-specific immune response against MUC1 and cancer-specific MUC1 antibody
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
FR2906808B1 (en) 2006-10-10 2012-10-05 Univ Nantes USE OF MONOCLONAL ANTIBODIES SPECIFIC TO THE O-ACETYLATED FORMS OF GANGLIOSIDE GD2 IN THE TREATMENT OF CERTAIN CANCERS
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
JP2010190572A (en) 2007-06-01 2010-09-02 Sapporo Medical Univ Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
US8379824B2 (en) 2008-03-06 2013-02-19 At&T Intellectual Property I, Lp Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2389443B1 (en) 2009-01-23 2018-11-14 Roger Williams Hospital Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
CN102421801B (en) 2009-03-10 2016-03-16 比奥根Ma公司 anti-BCMA antibody
ES2550639T3 (en) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anti-IL-3Ralpha antibody for use in the treatment of a blood tumor
JP5934099B2 (en) 2009-10-01 2016-06-15 アメリカ合衆国 Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptor and its use for the treatment of cancer
KR101692297B1 (en) 2009-10-20 2017-01-04 도오쿄 인스티튜드 오브 테크놀로지 Screening method utilizing thalidomide-targeting factor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CA2791975C (en) 2010-02-04 2021-02-09 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
CN105777907B (en) 2010-02-24 2020-03-17 伊缪诺金公司 Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
CA2816379A1 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5897035B2 (en) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア General-purpose anti-tag chimeric antigen receptor-expressing T cells and methods for treating cancer
JP2014509841A (en) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Compositions and methods for treating cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
ES2785081T3 (en) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Bispecific T-cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
AR086044A1 (en) 2011-05-12 2013-11-13 Imclone Llc ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
UA112434C2 (en) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед ANTIGENCY BINDING SPECIFICALLY Binds to ALL
CA2842798C (en) 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
MX2014001222A (en) 2011-07-29 2014-09-15 Univ Pennsylvania CHANGE CO-STIMULATING RECEIVERS.
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
KR20140060541A (en) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Rna engineered t cells for the treatment of cancer
JP6267644B2 (en) 2011-10-20 2018-01-24 アメリカ合衆国 Anti-CD22 chimeric antigen receptor
ITMO20110270A1 (en) 2011-10-25 2013-04-26 Sara Caldrer A MODELED EFFECTIVE CELL FOR THE TREATMENT OF NEOPLASIES EXPRESSING THE DISIALONGANGLIOSIDE GD2
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US9439768B2 (en) 2011-12-08 2016-09-13 Imds Llc Glenoid vault fixation
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc MODULATORS OF STROGEN RECEPTORS AND USES THEREOF
BR112014014767A2 (en) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc new benzopyran compounds, compositions and uses thereof
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112014020502A2 (en) 2012-02-22 2019-09-24 Univ Pennsylvania isolated nucleic acid sequence, isolated antigen chimeric receptor, cell, vector, and methods for stimulating an immune response, for providing antitumor immunity, for treating a mammal, for generating and expanding a population of t-cells, and to modulate the amount of cytokine secreted by a t-cell
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP2817330B1 (en) 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
IN2014MN02293A (en) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
EP2850106B1 (en) 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
WO2013192294A1 (en) 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
ES2872967T3 (en) * 2012-06-29 2021-11-03 Celgene Corp Methods to determine drug efficacy using IKZF3 (AIOLOS)
IN2014DN10889A (en) 2012-07-13 2015-09-11 Univ Pennsylvania
KR20150029714A (en) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Enhancing activity of car t cells by co-introducing a bispecific antibody
PL4019041T3 (en) 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Toxicity management for anti-tumor activity of cars
EP2872617A4 (en) 2012-07-13 2015-12-09 Univ Pennsylvania EXTENSION OF EPITOPES IN RELATION TO T CAR LYMPHOCYTES
KR20210149195A (en) 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Methods of assessing the suitability of transduced T cells for administration
MX382772B (en) 2012-07-13 2025-03-11 Univ Pennsylvania COMPOSITION FOR USE TO PREVENT OR DELAY TRANSPLANT REJECTION OF A TRANSPLANTED TISSUE OR ORGAN IN A SUBJECT.
JP6024953B2 (en) * 2012-07-25 2016-11-16 国立大学法人 岡山大学 Use of PINK1 for ubiquitination assay and screening
LT2884999T (en) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
JP6636803B2 (en) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Method for selection of antibodies to BCMA
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
US20160046718A1 (en) 2013-03-14 2016-02-18 Csl Limited Agents that neutralize il-3 signalling and uses thereof
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
ES2769574T3 (en) 2013-03-15 2020-06-26 Michael C Milone Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
EA031077B1 (en) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Estrogen receptor modulator and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
BR112015030595A2 (en) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2015077058A2 (en) * 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
ES2918501T3 (en) 2013-12-19 2022-07-18 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
KR20240164967A (en) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
EP3114217A4 (en) 2014-03-07 2017-09-20 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
CN122399016A (en) 2014-03-15 2026-07-17 诺华股份有限公司 Treatment of cancer using chimeric antigen receptor
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP4649963A3 (en) * 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
CN106456670B (en) 2014-04-25 2020-01-07 蓝鸟生物公司 Improved methods for producing adoptive cell therapy
BR112016024546A2 (en) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft antibody or antibody fragment, antibody or isolated antibody fragment, antibody-drug conjugate, nucleic acid molecule, host cell, and pharmaceutical composition
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
US20170073415A1 (en) 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
RS61406B1 (en) 2014-06-06 2021-03-31 Bluebird Bio Inc Improved t cell compositions
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3194585A1 (en) 2014-07-21 2017-07-26 Novartis AG Sortase molecules and uses thereof
BR112017000939A2 (en) 2014-07-21 2017-11-14 Novartis Ag cancer treatment using a cll-1 chimeric antigen receptor
JP6831777B2 (en) 2014-07-21 2021-02-17 ノバルティス アーゲー Treatment of cancer using the CD33 chimeric antigen receptor
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CN108055853A (en) * 2014-10-10 2018-05-18 达纳-法伯癌症研究所有限公司 Plasmids comprising internal ribosome entry sites and uses thereof
US20170239294A1 (en) 2014-10-15 2017-08-24 Novartis Ag Compositions and methods for treating b-lymphoid malignancies
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
HRP20210582T1 (en) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF ADMINISTRATION
CN113698497A (en) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 Chimeric antigen receptor targeting B-cell maturation antigen and uses thereof
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2016106244A1 (en) * 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
RU2751362C2 (en) 2014-12-29 2021-07-13 Новартис Аг Methods for producing cells expressing chimeric antigen receptor
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
PL3280729T3 (en) 2015-04-08 2022-08-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
TWI700298B (en) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 Chimeric antigen receptors targeting b-cell maturation antigen
HUE057285T2 (en) 2015-04-13 2022-04-28 Pfizer Therapeutic antibodies and their uses
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI833684B (en) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
JP2018524373A (en) 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド Drug-conjugated bispecific antigen-binding construct
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
TWI811023B (en) 2015-08-17 2023-08-01 美商健生生物科技公司 Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
JP6894430B2 (en) 2015-08-24 2021-06-30 セレクティスCellectis Chimeric antigen receptor with integrated regulatory function
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
CA2999070A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
CA3000661C (en) 2015-09-30 2024-04-02 Nigel H. Greig Thalidomide analogs and methods of use
PT3393504T (en) 2015-12-22 2025-12-30 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and anti-PD-L1 inhibitor antibody for combined use in anticancer therapy.
CA3009852A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20180099768A (en) 2015-12-30 2018-09-05 노파르티스 아게 Immune effector cell therapy with enhanced efficacy
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
US20230071283A1 (en) 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3484455A2 (en) 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
KR20230100748A (en) 2016-07-28 2023-07-05 노파르티스 아게 Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201900885VA (en) 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018053006A1 (en) 2016-09-13 2018-03-22 Dana-Farber Cancer Institute, Inc. Methods and compositions for the positive selection of protein destabilizers
WO2018059549A1 (en) 2016-09-30 2018-04-05 Novartis Ag Immune effector cell therapies with enhanced efficacy
JP7467117B2 (en) 2016-10-07 2024-04-15 ノバルティス アーゲー Chimeric antigen receptors for the treatment of cancer - Patents.com
CN109983027A (en) * 2016-10-20 2019-07-05 细胞基因公司 Heterodimerizable chimeric antigen receptors based on CEREBLON
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US12023385B2 (en) 2017-02-08 2024-07-02 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
RU2019133286A (en) 2017-03-22 2021-04-22 Новартис Аг BIOMARKERS AND THERAPIES BASED ON T-CELLS WITH CAR WITH INCREASED EFFICIENCY
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
IT201700057500A1 (en) * 2017-05-26 2018-11-26 Piaggio & C Spa Vehicle shock absorber unit with selective kinematic lock, vehicle suspension unit and related vehicle
GB201710620D0 (en) * 2017-07-03 2017-08-16 Glaxosmithkline Intellectual Property Ltd Targeted protein degradation
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
MX2020005651A (en) 2017-11-30 2020-10-28 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof.
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US20200061113A1 (en) 2018-04-12 2020-02-27 Novartis Ag Chimeric antigen receptor therapy characterization assays and uses thereof
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20200085869A1 (en) 2018-05-16 2020-03-19 Novartis Ag Therapeutic regimens for chimeric antigen receptor therapies
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag Bcma chimeric antigen receptors and uses thereof
SI3844267T1 (en) 2018-08-31 2025-10-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
JP7805928B2 (en) 2019-11-26 2026-01-26 ノバルティス アーゲー CD19 and CD22 chimeric antigen receptors and uses thereof
EP4104187A1 (en) 2020-02-14 2022-12-21 Novartis AG Method of predicting response to chimeric antigen receptor therapy
JP2023516008A (en) 2020-02-27 2023-04-17 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140090111A1 (en) * 2012-09-05 2014-03-27 Carnegie Institution Of Washington Plant Hormone Biosensors
WO2015127351A1 (en) * 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017044801A2 (en) * 2015-09-11 2017-03-16 The Broad Institute, Inc. Methods of identifying drug-modulated polypeptide targets for degradation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU, GANG, ET AL., THE MYELOMA DRUG LENALIDOMIDE PROMOTES THE CEREBLON-DEPENDENT DESTRUCTION OF IKAROS PROTEINS, 28 November 2013 (2013-11-28) *

Also Published As

Publication number Publication date
IL321733A (en) 2025-08-01
SG11202003415XA (en) 2020-05-28
AU2025283543A1 (en) 2026-01-22
MX2020004013A (en) 2021-01-08
CA3079407A1 (en) 2019-04-25
AU2018351050A8 (en) 2020-05-28
TWI829655B (en) 2024-01-21
AU2018351050B2 (en) 2025-09-18
BR112020007576A2 (en) 2020-09-24
EP3697436A1 (en) 2020-08-26
AR123115A1 (en) 2022-11-02
AU2018351050A1 (en) 2020-05-07
US20200339704A1 (en) 2020-10-29
RU2020115889A (en) 2021-11-18
JP7585034B2 (en) 2024-11-18
US11999802B2 (en) 2024-06-04
KR20200086278A (en) 2020-07-16
TW201922799A (en) 2019-06-16
IL273948B1 (en) 2025-08-01
IL273948A (en) 2020-05-31
WO2019079569A1 (en) 2019-04-25
CN111629749A (en) 2020-09-04
TW202428622A (en) 2024-07-16
JP2025037871A (en) 2025-03-18
US20240384007A1 (en) 2024-11-21
JP2021501570A (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL273948B1 (en) Compositions and methods for selective degradation of proteins
JP2025037871A5 (en)
JP2021501570A5 (en)
IL295878A (en) Methods of making chimeric antigen receptor-expressing cells
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
JP2019518424A5 (en)
RU2018122106A (en) BUFFERS FOR STABILIZING LENTIVIRUS DRUGS
KR20210126008A (en) Combination of Cellular Immunotherapy
CA3164666A1 (en) Bcma-directed cellular immunotherapy compositions and methods
US20230000913A1 (en) Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
KR20250030977A (en) Compositions and methods comprising chimeric adapter polypeptides
US20210079111A1 (en) Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
JP2019531742A5 (en)
EP4486373A1 (en) Allogeneic therapeutic cells
CN121311239A (en) Parallel chimeric antigen receptors (pCARs) containing alternative signal transduction domains and their adaptor chimeric antigen receptors and their usage methods
US20260085104A1 (en) Methods of detecting immune cells
EA050762B1 (en) ALLOGENEIC THERAPEUTIC CELLS
HK40115321A (en) Allogeneic therapeutic cells
RU2022122433A (en) COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION
JP2026514801A (en) Allogeneic therapeutic cells with reduced risk of immune rejection
RU2018140063A (en) COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION
AU2023343788A1 (en) Enrichment of engineered immune cells